Arrhythmias - Pipeline Review, H1 2016

Date: March 22, 2016
Pages: 55
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A6A02A68210EN
Leaflet:

Download PDF Leaflet

Arrhythmias - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Arrhythmias - Pipeline Review, H1 2016’, provides an overview of the Arrhythmias pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Arrhythmias, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Arrhythmias and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Arrhythmias
  • The report reviews pipeline therapeutics for Arrhythmias by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Arrhythmias therapeutics and enlists all their major and minor projects
  • The report assesses Arrhythmias therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Arrhythmias
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Arrhythmias
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Arrhythmias pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Arrhythmias Overview
Therapeutics Development
Pipeline Products for Arrhythmias - Overview
Pipeline Products for Arrhythmias - Comparative Analysis
Arrhythmias - Therapeutics under Development by Companies
Arrhythmias - Therapeutics under Investigation by Universities/Institutes
Arrhythmias - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Arrhythmias - Products under Development by Companies
Arrhythmias - Products under Investigation by Universities/Institutes
Arrhythmias - Companies Involved in Therapeutics Development
Cynata Therapeutics Limited
Gilead Sciences, Inc.
Ono Pharmaceutical Co., Ltd.
Orion Oyj
SciFluor Life Sciences, LLC
SignPath Pharma Inc
Arrhythmias - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
aladorian sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotides to Activate hERG1 for Long-QT Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
efsevin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
eleclazine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EU-8120 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GS-967 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KN-93 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
landiolol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LH-021 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ORM-10103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PP-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Arrhythmia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Antagonize Ryanodine Receptor 2 for Ventricular Arrhythmia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Cardiovacular Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VKII-86 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Arrhythmias - Recent Pipeline Updates
Arrhythmias - Dormant Projects
Arrhythmias - Discontinued Products
Arrhythmias - Product Development Milestones
Featured News & Press Releases
May 09, 2014: Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Arrhythmias, H1 2016
Number of Products under Development for Arrhythmias - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Arrhythmias - Pipeline by Cynata Therapeutics Limited, H1 2016
Arrhythmias - Pipeline by Gilead Sciences, Inc., H1 2016
Arrhythmias - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
Arrhythmias - Pipeline by Orion Oyj, H1 2016
Arrhythmias - Pipeline by SciFluor Life Sciences, LLC, H1 2016
Arrhythmias - Pipeline by SignPath Pharma Inc, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Arrhythmias Therapeutics - Recent Pipeline Updates, H1 2016
Arrhythmias - Dormant Projects, H1 2016
Arrhythmias - Dormant Projects (Contd..1), H1 2016
Arrhythmias - Discontinued Products, H1 2016

LIST OF FIGURES

Number of Products under Development for Arrhythmias, H1 2016
Number of Products under Development for Arrhythmias - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Targets, H1 2016
Number of Products by Stage and Targets, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016
Skip to top


Arrhythmias - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 55 pages
Axillary Hyperhidrosis - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 55 pages
Polycythemia Vera - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 75 pages
P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H1 2016 US$ 3,500.00 Jun, 2016 · 59 pages

Ask Your Question

Arrhythmias - Pipeline Review, H1 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: